Angiomax Generics Imminent After Court Rules Patents Are Invalid

Exactly when The Medicine Co.'s top seller will see competition isn't clear – highlighting industry concerns with FDA review times for ANDAs. Hospira and Sagent have tentative approval and several other firms have pending applications.

The Medicines Co. could face generic competition for its anticoagulant Angiomax (bivalirudin) four years earlier than expected now that the U.S. Court of Appeals for the Federal Circuit has ruled two patents covering the drug are invalid.

Last year, a district court found that Hospira Inc. failed to prove that claims in the patents were invalid...